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Abstract
Background: In Crohn’s disease high tissue expression and serum levels of chemokines and their receptors are known to
correlate with disease activity. Because statins can reduce chemokine expression in patients with coronary diseases, we
wanted to test whether this can be achieved in patients with Crohn’s disease.
Methodology/Principal Findings: We investigated plasma levels of chemokines (CCL2, CCL4, CCL11, CCL13, CCL17, CCL22,
CCL26, CXCL8, CXCL10) and endothelial cytokines (sP-selectin, sE-selectin, sICAM-3, thrombomodulin) in ten Crohn’s disease
patients before and after thirteen weeks’ daily treatment with 80 mg atorvastatin. Of the 13 substances investigated, only
CXCL10 was found to be significantly reduced (by 34%, p=0.026) in all of the treated patients. Levels of CXCL10 correlated
with C-reactive protein (r=0.82, p,0.01).
Conclusions/Significance: CXCL10 is a ligand for the CXCR3 receptor, the activation of which results in the recruitment of T
lymphocytes and the perpetuation of mucosal inflammation. Hence the reduction of plasma CXCL10 levels by atorvastatin
may represent a candidate for an approach to the treatment of Crohns disease in the future.
Trial Registration: ClinicalTrials.gov NCT00454545
Citation: Grip O, Janciauskiene S (2009) Atorvastatin Reduces Plasma Levels of Chemokine (CXCL10) in Patients with Crohn’s Disease. PLoS ONE 4(5): e5263.
doi:10.1371/journal.pone.0005263
Editor: Antje Timmer, HelmholtzZentrum Mu ¨nchen, Germany
Received December 23, 2008; Accepted March 2, 2009; Published May 6, 2009
Copyright:  2009 Grip, Jancianskiene. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by grants from the Medical Faculty of Lund, Region Skane, the Medical Research Council and the Lundstrom Foundation. The
funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.




Over the past years, investigators from many scientific
disciplines have demonstrated that the scope of chemokine
function extends far beyond their chemoattractant moieties.
Consequently, a growing number of reports indicate their crucial
roles in a variety of diseases, among others renal diseases,
rheumatoid arthritis, arteriosclerosis, multiple sclerosis and
chronic inflammatory bowel diseases (IBD) [1]. Chemokines can
be classified, based on functional criteria, into inflammatory and
homeostatic. Typical examples of inflammatory chemokines
include CCL2, CCL3, CCL4, CCL5, CCL11, CXCL8 and
CXCL10. These chemokines play an important role in both
innate and adaptive immunity, and are expressed by the
circulating leukocytes and other cells only in response to infection,
tissue damage or specific mediators, such as tumor necrosis factor,
interferon-c and microbial products [2]. In contrast, homeostatic
chemokines, such as CCL19, CCL21 and CXCL12, are
constitutively expressed in order to coordinate cell migration and
development of the immune system [3].
It is postulated that during inflammation chemokines attract
specific subsets of leukocytes according to their expression of
chemokine receptors [4]. For example, in the case of T cells, the
chemokines CCL17 and CCL22 are ligands for the chemokine
receptor CCR4, whereas CCL1 is a ligand for CCR8 expressed on
a subset of Th2 cells [5]. CXCL10 and CXCL11 are ligands for
CXCR3, expressed on Th1 cells [6]. Specific chemokines and
their receptors are expressed on different cell types, and therefore,
relative differences in receptor distribution and affinity for specific
chemokines may significantly influence which cells are ultimately
attracted to and activated by the individual chemokine.
Chemokine activation requires a complex cascade of steps,
including phosphorylation by multiple kinases and phosphatases,
degradation of transcriptional inhibitors, translocation of tran-
scription factors from cytoplasm to nucleus, etc. [7]. These
biochemical events are potential targets for therapeutic interven-
tion. For example, glucocorticoids interfere with nuclear factor,
NF-kappaB, activation and are effective in reducing chemokine
production [8]. Similarly, agents that influence cAMP levels often
modulate the stimulatory signals for chemokine expression [9,10].
Various studies indicate that statins express anti-inflammatory
properties and may play a role in modulating the immune system
[11]. In patients with coronary artery disease, statins (atorvastatin)
were found to significantly reduce expression of chemokines (i.e.,
CCL3, CCL4 and CXCL8) and their receptors (i.e., CCR1 and
CCR2) [12]. Statin-induced reductions in CRP have been shown
in patients with and without established cardiovascular disease
[13]. We have also previously shown that atorvastatin reduces
PLoS ONE | www.plosone.org 1 May 2009 | Volume 4 | Issue 5 | e5263plasma CRP levels and inflammation in patients with Crohn’s
disease (CD) [14,15]. Several chemokines and their receptors are
described to have a connection with IBD and to correlate with
activity of the disease [16,17,18]. So far, effects of statins on the
chemokine production in IBD have not been investigated.
Therefore, we aimed at evaluating the effects of atorvastatin on
plasma chemokine levels in CD patients. We show for the first time
that high-dose oral intake of atorvastatin (80 mg per day)
significantly reduces plasma CXCL10, but not the other
chemokines measured. Hence blocking the production of
CXCL10 by atorvastatin may represent a candidate for a new
approach to the treatment of CD in the future.
Results
Study population
Table 1 presents the characteristics of the 10 patients who
participated in the study. Their median age was 32 years (range,
23–44 y), and the median disease duration was 4.5 years.
Plasma Levels of Cytokines and Chemokines
Table 2 and 3 show the results of the analysis of nine
inflammatory chemokines and four endothelial cytokines in the
patients. The top three (CXCL10, CCL4 and CCL22) in table 1
and thrombomodulin in table 2 show separately significant
differences between the baselines and at the end of the treatment.
Although these results are of some interest in their own right, the
greatest separation was found for CXCL10 and, when corrected
for multiple analyses, this was the only statistically proven
difference, presented separately in figure 1. As seen in this graph
all patients responded with a reduction in CXCL10 levels and the
gradient did not differ between those with a higher and those with
a lower CXCL10 baseline level. The mean reduction of the five
patients with the highest levels was 27 percent and for the five with
the lowest levels it was 31 percent. Thus, although our material is
too small to subdivide into groups, our findings indicate that the
effect of statin is not related to the baseline levels of CXCL10.
Association between plasma CXCL10 versus systemic and
local markers of inflammation
To determine the relationship of CXCL10 with regard to
known markers of systemic and intestinal inflammation in CD we
correlated CXCL10 to the C-reactive protein (CRP) and the fecal
calprotectin levels previously described in the patients [15]. At
baseline the levels of CRP were 8.8 (5.7–14.4) mg/L whereas at
the end of treatment the CRP levels were significantly reduced 4.9
(3.3–6.2) mg/L (p,0.01). Fecal calprotectin, a marker for
intestinal inflammation, was found to be reduced after treatment
in 8/10 patients [734 (251–1233) vs 384 (151–958) mg/kg],
p=0.23. Plasma CRP and CXCL10 were found to correlate
before (r=0.66, p,0.05) and after (r=0.82, p,0.01) treatment
with atorvastatin. It can be noted that after treatment the
correlation was also found between CRP and calprotectin
(r=0.78, p,0.01) but not between CXCL10 and calprotectin.
As described in our previous publication, atorvastatin treatment
gives a profound hypocholesterolemic effect in CD patients [15].
However, we found no relation between plasma CXCL10 levels
and total cholesterol, apolipoprotein B or trigycerids, either at
baseline or at the end of treatment with atorvastatin (Pearson
product moment correlation calculations, p.0.05).
Discussion
We have previously published results showing that high-dose
intake of atorvastatin reduces plasma levels of CRP and clinical
disease activity in CD patients [15]. Infiltration of leukocytes is a
prominent histological feature of CD and the up-regulated
chemokine expression correlates with increasing activity of the
CD [19,20]. On this basis we therefore hypothesized that the
reduction of the CD activity achieved by the atorvastatin
treatment may be related to its ability to reduce chemokine levels.
The chemokines we measured have a connection with inflamma-
tory bowel diseases, although some of them have not been shown
to be elevated in plasma [16,17,18]. Our results show for the first
time that intake of atorvastatin significantly reduces plasma levels
of CXCL10 in patients with CD.
Chemokines and their receptors are molecules that may manage
selective migration of particular T-cell subsets. Lymphocytes that
change to IFN-c producing Th1 effector cells express chemokine
receptors such as CCR5 and CXCR3 [21]. High CXCR3
expression was originally thought to be restricted to activated T
lymphocytes [22], however, later findings show that expression of
CXCR3 can be detected in endothelial cells, dendritic cells, as well
as in neutrophils and eosinophils within tissues dominated by Th1
[23,24]. Both animal studies [25] and studies in CD patients [26]
confirm the generally accepted assumption that CD is primarily a
condition in which the Th1/Th17-type is dominant involving up-
regulation of IFN-c and IL-12 production [27].
Table 1. Demographic data of patients.
Age (Years) Sex Duration of Disease (Years) Involvement Smoking IBD-related drugs
24 F 1 Ileocolonic yes Bud
25 F 12 Ileocecal no AZA
31 F 1 Ileocolonic no 5-ASA
42 F 8 Ileocolonic no Pred/5-ASA
44 F 1 Oesophagus to rectum yes
23 M 0.5 Ileal and rectal no Bud
27 M 0.5 Ileocolonic yes
33 M 15 Ileocolonic no
35 M 1 Ileal no Bud
40 M 8 Ileal yes
IBD, inflammatory bowel disease; 5-ASA, 5-aminosalicylate; AZA, azathioprine; Bud, budesonide; Pred, prednisolone.
doi:10.1371/journal.pone.0005263.t001
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their chemotactic functions by interacting with the chemokine
receptor, CXCR3. CXCL10 is an immediate-early gene that is
induced by IFN-c and is produced by various cell types involved in
leukocyte trafficking, such as epithelial cells [28]. The association
among CXCL10, CXCR3, and Th1-dependent immunity has
been observed in several models of inflammatory diseases.
Therefore, there is a growing interest in the CXCL10-CXCR3
Figure 1. Plasma levels of CXCL10/IP-10 in ten Crohn’s disease patients at baseline and after thirteen weeks’ treatment with 80 mg
atorvastatin daily, *P,0.05.
doi:10.1371/journal.pone.0005263.g001
Table 2. Median plasma levels of chemokines at baseline and after 13 weeks’ treatment with atorvastatin.
Baseline (q1–q3) (pg/mL) End of treatment (q1–q3) (pg/mL) D% Number of patients with a reduction P
CXCL10/IP-10 240.1 (189.4–325.1) 158.0 (133.3–232.5) 234 10/10 0.026
CCL4/MIP-1b 312.0 (283.1–387.3) 252.1 (219.4–283.6) 219 9/10 0.058
CCL22/MDC 7728.2 (5755.5–9901.1) 6544.3 (3671.1–9598.1) 215 9/10 0.490
CCL26/Eotaxin-3 43.5 (41.4–45.7) 31.8 (23.1–34.3) 227 8/10 0.922
CCL11/Eotaxin 526.1 (404.0–723.0) 463.5 (316.0–560.7) 212 7/10 0.512
CXCL8/IL-8 9.3 (6.2–12.3) 7.0 (4.3–9.7) 225 7/10 0.588
CCL17/TARC 446.4 (266.1–708.8) 380.3 (211.4–537.5) 215 7/10 0.922
CCL2/MCP-1 126.0 (99.8–127.8) 107.9 (90.9–150.8) 214 5/10 0.922
CCL13/MCP-4 450.6 (140.7–584.2) 272.6 (117.9–693.1) 240 4/10 0.922
P, corrected for multiple analyses.
doi:10.1371/journal.pone.0005263.t002
Table 3. Median plasma levels of endothelial cytokines at baseline and after 13 weeks’ treatment with atorvastatin.
Baseline (q1–q3) (ng/mL) End of treatment (q1–q3) (ng/mL) D% Number of patients with a reduction P
Thrombomodulin 2.1 (1.9–2.2) 1.9 (1.7–2.0) 210 8/10 0.407
sP-Selectin 243.3 (190.9–332.2) 215.3 (197.7–253.1) 212 7/10 0.512
sICAM-3 5.3 (4.7–7.4) 4.9 (4.5–5.5) 28 6/10 0.922
sE-Selectin 17.5 (12.6–24.7) 15.0 (8.7–20.9) 214 5/10 0.922
P, corrected for multiple analyses.
doi:10.1371/journal.pone.0005263.t003
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expression of chemokines, such as CCL2, CCL3, CCL4, CCL7,
CCL8 and CXCL8 has been shown in mucosal biopsies from
patients with CD and ulcerative colitis, and this up-regulation
correlated with the disease activity [29]. As a confirmation of this,
others have shown that CXCR3 and the ligands for this receptor,
CXCL9 and CXCL10, are up-regulated in tissues from CD
patients [30]. Similarly, serum levels of CXCL9, CXCL10 and
CXCL11 were found to be significantly higher in CD patients as
compared to healthy controls [31]. Studies in animal models have
also shown that the leukocyte-derived CXCL10 is associated with
chronic colitis, and that the blockade of CXCL10 with anti-
CXCL10 antibody may abrogate the inflammatory response
[32,33]. Therefore, specific agents capable of inhibiting chemokine
synthesis and secretion or blocking chemokine–chemokine recep-
tor interaction are of particular interest in the study of patients
with ulcerative colitis and CD.
Previous studies have reported a reduction of plasma chemo-
kines (i.e CCL2, CCL4, CXCL8) in patients with cardiovascular
disease treated with statins [12,34]. Notably in our study, we
observed no statistically significant changes in plasma CCL2, and
other chemokine (i.e. CCL11, CCL13, CCL17, CCL22 and
CCL26) levels in CD patients treated with atorvastatin. In
addition, in our CD patient group atorvastatin shows no effect
on adhesion molecules linked to leukocyte trafficking, such as E-
selectin, P-selectin and ICAM-3, whereas in cardiovascular disease
patients these adhesion molecules can be reduced by the statin
therapy [35,36,37]. One can only speculate that the reason for
these differences may reflect different effects of statins in relation to
dosage, and co-treatments, and may reflect differences between
the statin used, since all statins may not have the same therapeutic
potential. Moreover, the effect of statins may vary between
different inflammatory conditions depending on the status of
inflammation and the cellular source of the chemokines and
adhesion molecules. For example, some statins even have differing
effects on protein expression in the same cell type: in monocytes
stimulated by lipopolysaccharide, pravastatin and fluvastatin may
induce the production of TNF-a [38,39], whereas atorvastatin and
simvastatin inhibit the production of TNFa [40].
Previous studies have shown that in CD patients the expression
of mucosal microvasculature adhesion markers, such as CAMs, are
increased [41], and a high expression of thrombomodulin, another
marker of the microvasculature activation, has also been shown in
CD patients [42]. There are publications showing that serum
levels of E-selectin are not changed in CD whereas sP-selectin
levels are dependent on disease activity [43,44]. Thus, our findings
that atorvastatin did not significantly decrease plasma levels of the
soluble selectins and the thrombomodulin do not exclude the
possibility that statin may affect the local expression of these
proteins. On the other hand the study maybe underpowered to
show less pronounced changes.
Taken together our data allow us to speculate that treatment of
CD patients with atorvastatin not only lowers plasma CRP, a
marker of systemic inflammation, but also specifically lowers levels
of plasma chemokine, CXCL10. The reduction in CXCL10 levels
after atorvastatin treatment has, to date, only been found in
monocyte and epithelial cell culture models, in vitro [45]. Since
there are no reports regarding the effects of statins on this
chemokine in patients with inflammatory bowel diseases, we are
not able to conclude whether our finding is specifically related to
CD patients.
There are several possible pathways through which statins could
reduce chemokine synthesis and release. For example, by
inhibiting HMG-CoA reductase, statins can block the synthesis
of important isoprenoid intermediates, which are necessary for the
post-translational lipid modification (prenyalation) of a variety of
intracellular signaling molecules [46]. In particular, the inhibition
of small guanosine triphosphate (GTP)-binding proteins Rho, Ras,
and Rac, whose proper localisation and function in the membrane
are dependent upon isoprenylation, plays an important role in
signal transduction pathways that regulate cell proliferation, cell
differentiation, vesicular transport and apoptosis [47]. Thus, the
inhibitory effect on chemokine-induced migration by statins can be
explained by these mechanisms since both the MAPK cascade, the
NF-kB and the JNK pathways, which regulate expression and
release of chemokines [48], are activated by Rho-GTPases
[49,50,51].
Although chronic inflammatory diseases, including IBD, are
associated with increased expression of specific chemokines and
their receptors, the role these chemokines play in disease severity,
susceptibility and progression is not certain. Furthermore, the
analysis of chemokine levels in plasma may reflect the general
inflammatory status but not the event at the specific site, i.e. the
intestine. Whether the CXCL10 we measure in the plasma can
promote specific T-cell migration into the gut remains to be
determined. Yet the relevance of plasma CXCL10 levels in our
study is supported by its close correlation to CRP, which is an
established marker of intestinal inflammation in CD patients [52].
In conclusion we show, that atorvastatin significantly decreases
plasma levels of CXCL10 in CD patients but the question whether
this is a specific effect is still open for discussion. CXCL10 is an
important ligand for the CXCR3 receptor on lymphocytic cells,
the activation of which may result in the recruitment of T
lymphocytes and the perpetuation of chronic mucosal inflamma-
tion. Thus we believe that our finding describes a new, important
in vivo function of atorvastatin and also provides further support for
the use of statins in therapy for patients with CD.
Materials and Methods
Study Participants
The patients and the design of the clinical trial have previously
been described [15]. In short, ten patients (5 women and 5 men)
with a confirmed diagnosis of Crohn’s disease were given a
supplementary treatment of 80 mg atorvastatin (Pfizer, Sollen-
tuna, Sweden) once daily. All baseline drugs were kept unchanged.
Plasma samples were taken prior to treatment and after 13 weeks’
treatment. Analysis was done at the termination of the treatment
and plasma was stored during the study at 220uC. The study was
approved by the Medical Products Agency, the Regional Ethical
Review Board and was performed in accordance with good
clinical practice (monitored by RSKC, Region Ska ˚ne). Written
informed consent was obtained from all participants. The study
was registered at ClinicalTrials.gov: NCT00454545. We would
like to notify, that studies using statins therapy on CD patients
have not been performed previously and we had no reference, and
therefore, for ethical reasons we did not want to start treatment on
a large number of CD patients. We wanted first to know that CD
patients, who were willing to participate in the study, were getting
the right drug at the right dose, and tolerated this drug well. The
patient flowchart and the protocol for this trail is available as
supporting information; see Flowchart S1 and Protocol S1.
Cytokine Multiplex Analysis
Plasma levels of chemokines and vascular cytokines were assessed
by MesoScale technology, which is a multiplex type of ELISA
technology that relies on electrochemiluminescence, according to
the manufacturer’s protocol. Briefly, specific antibodies that coat a
Chemokines in CD Patients
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interest. A second antibody labelled with a SULFO-TAG
TM binds
the molecule of interest. The SULFO-TAG
TM emits light upon
electrochemical stimulation when a current is applied between the
counter electrode and the working electrode, and is registered by a
SECTORT
TM Imager. Detection limits, LODs (Limits Of
Detection) are defined as 2.56 the standard deviation above the
background as calculated by MesoScale DiscoveryH: CCL2/MCP-
1, 3.3 pg/mL; CCL4/MIP-1b, 14 pg/mL; CCL11/Eotaxin,
10 pg/mL; CCL13/MCP-4, 19 pg/mL; CCL17/TARC, 8 pg/
mL; CCL22/MDC, 234 pg/mL; CCL26/Eotaxin-3, 14 pg/mL;
CXCL8/IL-8, 0.25 pg/mL; CXCL10/IP-10, 64 pg/mL. The
LODs for the vascular cytokines are: sP-selectin, 0.01 ng/mL; sE-
selectin, 0.02 ng/mL; sICAM-3, 0.05 ng/mL; thrombomodulin,
0.08 ng/mL.
Statistical analysis
Assay results are expressed as medians with the interquartile
ranges (q1,q3) specified in the tables. Pair-wise comparisons were
done by the Wilcoxon signed rank test between baselines vs. after
13 weeks’ treatment using SigmaStat 3.1 software (Systat Software
Gmbh, Germany). Corrections for multiple analyses were done by
the Benjamini and Hochberg false discovery rate. Correlation
analyses were done by the Pearson product moment. A P-
value,0.05 was regarded as significant.
Supporting Information
Flowchart S1 Consort Flowchart
Found at: doi:10.1371/journal.pone.0005263.s001 (0.03 MB
DOC)
Protocol S1
Found at: doi:10.1371/journal.pone.0005263.s002 (0.17 MB
DOC)
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